MapLight Therapeutics, Inc.
- Last sale
- Oct 30, 2026 · -1.94%
- Market cap
- $422.53M
- 55.67M shares
- Filings
- 216
—
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+22.2% FY25 yoy
- $422.53M
- —
- —
- 0.9×
- -32.80%
- —
FY2025 figures · derived
Price
Oct 30, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $138,349,000 | reported | |
| FY 2024 | 2024-12-31 | $68,523,000 | reported |
Pharmaceutical preparations
MapLight Therapeutics, Inc. is the 211th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
VREOFVireo Growth Inc.$268.8M170.4%25.3%$379.7MRZLTRezolute, Inc.———$374.8MPEPGPepGen Inc.———$350.5M
MPLTMapLight Therapeutics, Inc. (this company)———$344.9M
CYDYCytoDyn Inc.———$338.0MAVIRAtea Pharmaceuticals, Inc.———$330.0MBNTCBenitec Biopharma Inc.———$329.4MENTAEnanta Pharmaceuticals Inc$65.3M3.4%125.4%$325.8MGALTGalectin Therapeutics Inc———$314.7MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
MapLight Therapeutics, Inc. · CIK 1770069 · Engraved from SEC EDGAR